Inhaled Ibuprofen to Treat COVID-19

  • STATUS
    Recruiting
  • participants needed
    40
  • sponsor
    Química Luar SRL
Send
Updated on 5 August 2020
See if I qualify
pulmonary disease
cardiovascular disease
asthma
ibuprofen
pneumonia
chronic disease
chronic obstructive pulmonary disease
COPD
covid-19
lung injury
SARS
acute respiratory syndrome (sars)
diabetes

Summary

The study aims to evaluate the reduction in severity and progression of lung injury with inhaled ibuprofen in patients with severe acute respiratory syndrome due to SARS-CoV-2 virus.

Details
Condition Coronavirus Infection, SARS coronavirus, Respiratory Tract Diseases, Respiratory disorder, Severe Acute Respiratory Syndrome
Age 18years - 100years
Treatment Inhaled Hypertonic ibuprofen
Clinical Study IdentifierNCT04382768
SponsorQuímica Luar SRL
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

Provision of written informed consent by the patient OR by the patient's Legal Representative
Confirmed or suspected SARS-CoV-2 infection
Pneumonia without criteria of severity
With some of the following conditions
Diabetes
Cardiovascular disease
Chronic kidney disease
Chronic obstructive pulmonary disease
Structural diseases of the lung
Immunocompromise
Patient who presents negative results by rtPCR for SARS CoV-2, in case of being highly suspicious, the patient may receive it empirically until the results are obtained
No unstable bronchial asthma

Exclusion Criteria

The doctor considers that participation in the Program is not the best for patients or for any condition that prevents the Program from being followed safely
Patients with a history of unstable bronchial asthma
The patient is allergic to ibuprofen or any of the compounds in the preparation
Hypersensitivity to the drug, nasal polyps syndrome, angioedema or bronchospasm against aspirin or other NSAIDs
Pregnant or lactating woman, or positive pregnancy test on a pre-dose exam
Patient who is expected to be transferred to another place other than the place where the Program starts, within 7 days of starting it
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

pulmonary disease
cardiovascular disease
asthma
ibuprofen
pneumonia
chronic disease
chronic obstructive pulmonary disease
COPD
covid-19
lung injury
SARS
acute respiratory syndrome (sars)
diabetes

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.